PARP1 and neoplasm: In this review, we discuss the fundamental mechanisms underlying the efficacy of PARP inhibitors against DDR pathways in prostate cancer cells, the clinical aspects of PARP inhibitors in prostate cancer, and their role in the tumor microenvironment.